Literature DB >> 19127486

Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease?

Elsa Isingrini1, Thomas Desmidt, Catherine Belzung, Vincent Camus.   

Abstract

Depression and Alzheimer's disease (AD) are among the most prevalent mental disorders in the elderly. Strong evidence suggests that vascular diseases and vascular risk factors are associated with both depression and AD, and could partially explain the coexistence or the concurrent onset of these two diseases. In particular, endothelial dysfunction appears to play a critical role in the neurobiology of depression and amyloid deposition in the brains of patients with AD. Antidepressants have a significant impact on endothelial function. In addition, several drugs used to treat vascular disease or vascular risk factors, such as calcium-channel blockers, angiotensin-converting enzyme inhibitors and statins, have, to variable extents, significant clinical effects on depressive symptomatology or amyloid deposition in AD. Furthermore, preclinical and clinical data suggest that the nitric oxide and VEGF signaling pathways may be of value for the treatment of depression and AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19127486

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  12 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 2.  The impact of vascular burden on late-life depression.

Authors:  Micaela Santos; Enikö Kövari; Patrick R Hof; Gabriel Gold; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  Brain Res Rev       Date:  2009-09-08

3.  Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats.

Authors:  Bhupesh Sharma; Nirmal Singh
Journal:  Psychopharmacology (Berl)       Date:  2011-01-12       Impact factor: 4.530

4.  Depression-like behavior in subclinical hypothyroidism rat induced by hemi-thyroid electrocauterization.

Authors:  Jin-Fang Ge; Yun-Yun Peng; Cong-Cong Qi; Fang-Han Chen; Jiang-Ning Zhou
Journal:  Endocrine       Date:  2013-06-21       Impact factor: 3.633

5.  Brain Tissue Pulsatility is Increased in Midlife Depression: a Comparative Study Using Ultrasound Tissue Pulsatility Imaging.

Authors:  Thomas Desmidt; Bruno Brizard; Paul-Armand Dujardin; Redouane Ternifi; Jean-Pierre Réméniéras; Frédéric Patat; Frédéric Andersson; Jean-Philippe Cottier; Emilie Vierron; Valérie Gissot; Kang Kim; Howard Aizenstein; Wissam El-Hage; Vincent Camus
Journal:  Neuropsychopharmacology       Date:  2017-06-06       Impact factor: 7.853

6.  Role of inflammatory cytokines in depression: Focus on interleukin-1β.

Authors:  Rai Khalid Farooq; Kashif Asghar; Shahzina Kanwal; Ali Zulqernain
Journal:  Biomed Rep       Date:  2016-11-10

7.  Expression level of vascular endothelial growth factor in hippocampus is associated with cognitive impairment in patients with Alzheimer's disease.

Authors:  Huidong Tang; XiaoOu Mao; Lin Xie; David A Greenberg; Kunlin Jin
Journal:  Neurobiol Aging       Date:  2012-11-24       Impact factor: 4.673

Review 8.  Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease.

Authors:  Paula Grammas
Journal:  J Neuroinflammation       Date:  2011-03-25       Impact factor: 8.322

Review 9.  Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease.

Authors:  Daniah Shamim; Michael Laskowski
Journal:  J Cent Nerv Syst Dis       Date:  2017-07-28

10.  Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.

Authors:  Yuan-Yuan Zhang; Yu-Chen Fan; Min Wang; Dong Wang; Xiao-Hong Li
Journal:  Clin Interv Aging       Date:  2013-01-31       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.